Adapter protein SH2-B beta undergoes nucleocytoplasmic shuttling: Implications for nerve growth factor induction of neuronal differentiation by Chen, LY
MOLECULAR AND CELLULAR BIOLOGY, May 2004, p. 3633–3647 Vol. 24, No. 9
0270-7306/04/$08.000 DOI: 10.1128/MCB.24.9.3633–3647.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Adapter Protein SH2-B Undergoes Nucleocytoplasmic Shuttling:
Implications for Nerve Growth Factor Induction of
Neuronal Differentiation
Linyi Chen and Christin Carter-Su*
Department of Molecular and Integrative Physiology, University of Michigan Medical School,
Ann Arbor, Michigan 48109-0622
Received 22 August 2003/Returned for modification 18 September 2003/Accepted 5 February 2004
The adapter protein SH2-B has been shown to bind to activated nerve growth factor (NGF) receptor TrkA
and has been implicated in NGF-induced neuronal differentiation and the survival of sympathetic neurons.
However, the mechanism by which SH2-B enhances and maintains neurite outgrowth is unclear. We examined
the ability of truncation mutants to regulate neuronal differentiation and observed that certain truncation
mutants localized in the nucleus rather than in the cytoplasm or at the plasma membrane as reported for
wild-type SH2-B. Addition of the nuclear export inhibitor leptomycin B caused both overexpressed wild-type
and endogenous SH2-B to accumulate in the nucleus of both PC12 cells and COS-7 cells as did deletion of
a putative nuclear export sequence (amino acids 224 to 233) or mutation of two critical lysines in that sequence.
Deleting or mutating the nuclear export signal caused SH2-B to lose its ability to enhance NGF-induced
differentiation of PC12 cells. Neither the NGF-induced phosphorylation of ERKs 1 and 2 nor their subcellular
distribution was altered in PC12 cells stably expressing the nuclear export-defective SH2-B(L231A, L233A).
These data provide strong evidence that SH2-B shuttles constitutively between the nucleus and cytoplasm.
However, SH2-B needs continuous access to the cytoplasm and/or plasma membrane to participate in NGF-
induced neurite outgrowth. These data also suggest that the stimulatory effect of SH2-B on NGF-induced
neurite outgrowth of PC12 cells is either downstream of ERKs or via some other pathway yet to be identified.
Nerve growth factor (NGF) is a trophic factor essential for
the development and maintenance of sympathetic and sensory
neurons. The PC12 cell line, derived from a rat pheochromo-
cytoma arising from chromaffin cells of the adrenal medulla, is
a well-established model for studying neuronal differentiation
and cell signaling. Progressively, NGF-treated PC12 cells cease
proliferation, exhibit somatic hypertrophy, acquire neurites,
differentiate, and depend on NGF for survival (for a review,
see reference 52). The signal that initiates neuronal differen-
tiation starts with NGF binding to the receptor tyrosine kinase
TrkA and activating TrkA. The activated TrkA autophosphor-
ylates, and the phosphorylated tyrosines in the TrkA cytoplas-
mic domain serve as anchors for downstream signaling mole-
cules (5, 49).
Several signaling molecules have been shown to become
phosphorylated and activated in response to NGF, including
the adapter protein Shc, the Suc-associated neurotrophic fac-
tor-induced tyrosine-phosphorylated targets (SNTs, also called
FRS2), phospholipase-C (PLC-), and phosphatidylinositol-
3-kinase (PI3K) (5, 10, 16, 34, 35, 40, 60). Shc binds to phos-
phorylated tyrosine 490 in TrkA. Once phosphorylated by
TrkA, Shc binds Grb2/SOS complexes which initiates activa-
tion of the Ras/Raf/MEK pathway that leads to activation of
the mitogen-activated protein kinases (MAPKs) designated
extracellular regulated kinases (ERKs) 1 and 2 (13, 14, 58, 59).
SNTs are early markers for neuronal differentiation. Like Shc,
they recruit Grb2 adapter proteins in complex with SOS and
Ras as well as the SH2 domain-containing protein tyrosine
phosphatase SHP2. These interactions have been suggested to
be important in maintaining sustained activation of ERKs
1 and 2 and thus the differentiation of PC12 cells (60). The
binding of PLC- to TrkA regulates the production of diacyl-
glycerol and inositol triphosphate, leading to release of intra-
cellular Ca2 stores and activation of protein kinase C (5, 8, 37,
43, 57). Mobilization of Ca2 is thought to regulate growth cone
function and neurite outgrowth (4, 11, 23, 64). Activation of
PI3K and its downstream effector, the serine/threonine kinase
AKT/PKB, has been implicated in the assembly of basic helix-
loop-helix transcription factor-coactivator complexes and their
ability to promote neurogenesis in P19 cells (53).
We and others identified the putative adapter/scaffold pro-
tein SH2-B as a binding partner of TrkA as well as of the re-
ceptors for insulin, insulin-like growth factor 1, platelet-derived
growth factor, fibroblast growth factor, hepatocyte growth fac-
tor, and the cytokine receptor-associated JAK tyrosine kinases
(25, 26, 39, 41, 42, 44, 46, 54, 63). SH2-B belongs to a family of
adapter proteins that include APS and Lnk (19, 21, 62, 63).
The four SH2-B isoforms, , , , and , identified so far differ
only in their C termini starting just past the SH2 domain (33,
63). SH2-B contains three proline-rich domains, a pleckstrin
homology (PH) domain and a Src homology (SH2) domain; it
is the C-terminal SH2 domain that binds to the receptor tyro-
sine kinases (RTKs).
SH2-B  and  isoforms have been shown to be essential for
NGF-induced neurite outgrowth in PC12 cells (39, 46), and
SH2-B has been implicated in the survival of rat sympathetic
neurons (39). NGF enhances the association of SH2-B with
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TrkA and the tyrosine phosphorylation of SH2-B (39, 46).
Deletion analysis suggests that N-terminal amino acids (100 to
235) of SH2-B are required for forming homomultimers of
SH2-B and that multimers of SH2-B may be required for
SH2-B regulation of NGF-induced TrkA and MAPK activity
(38). The ability of SH2-B to bind TrkA via its SH2 domain
appears to be critical for NGF-induced neurite outgrowth in
PC12 cells. A point mutation in the FLVR motif within the
SH2 domain of SH2-B that changes Arg 555 to Glu [SH2-
B(R555E)] prevents the association of SH2-B with TrkA as
well as the tyrosine phosphorylation of SH2-B (47). While
overexpression of SH2-B enhances NGF-induced neurite
outgrowth of PC12 cells, overexpressing the SH2-B(R555E)
mutant abolishes it (46, 47). Curiously, overexpressing SH2-
B(R555E) does not inhibit the tyrosyl phosphorylation of
TrkA, Shc, PLC-, or ERKs 1 and 2 in response to NGF
stimulation (47). This latter finding raises the possibility that
SH2-B modulates neuronal differentiation via mechanisms
other than through PLC- and ERKs 1 and 2 or downstream
of those pathways.
To gain insight into the mechanism(s) by which SH2-B
enhances neurite outgrowth of PC12 cells, we set out to inves-
tigate further which domain(s) or region(s) of SH2-B is re-
sponsible for enhancing neurite outgrowth. During this analy-
sis, we obtained evidence suggesting that SH2-B shuttles
between the cytoplasm and the nucleus and identified a nu-
clear export signal. The fact that deletion or mutation of the
nuclear export signal abolished the ability of SH2-B to en-
hance NGF-induced neurite outgrowth of PC12 cells suggest
that cytoplasmic localization of SH2-B is required for this
stimulatory effect.
MATERIALS AND METHODS
Antibodies and reagents. Polyclonal antibody against green fluorescent pro-
tein (GFP) was from Clontech. Polyclonal antibody to rat SH2-B was raised
against a glutathione S-transferase fusion protein containing amino acids 527 to
670 of SH2-B as described previously (48). Polyclonal antibody against active
ERKs 1 and 2 (pThr202 and pTyr204) was purchased from either Promega (for
immunostaining) or from Cell Signaling (Western blot). The anti-phospho-TrkA
(Y490) was from UBI, and the poly-L-lysine was from Sigma. NGF (mouse) and
rat tail collagen were purchased from BD Bioscience. Lipofectamine and the
Plus reagent were from Invitrogen.
Plasmids. The N-terminal truncation mutants of GFP-tagged SH2-B (GFP-
SH2-B), GFP-SH2-B(170-670), GFP-SH2-B(200-670), GFP-SH2-B(270-
670), GFP-SH2-B(397-670), and GFP-SH2-B(504-670), were constructed by
generating via PCR mutagenesis BamHI sites at amino acids 168 to 169, 267 to
268, 395 to 396, and 502 to 503, respectively, using GFP-SH2-B as a template.
These mutants were then digested with BamHI and EcoRI. The purified BamHI-
and EcoRI-digested SH2-B fragments were inserted into the BglII- and EcoRI-
digested pEGFP-C1 vector. GFP-SH2-B(198-268) was made by generating
BamHI sites at amino acids 198 and 199 and amino acids 267 to 268 using
GFP-SH2-B as a template. Fragments from NheI, BamHI, and BamHI plus
EcoRI digestions of this mutant were purified. The resulting two fragments, 1.2
and 1.77 kb, were then ligated to NheI- and EcoRI-cut pEGFP-C1 vector (4 kb)
to make the final GFP-SH2-B(198-268) construct. The construction of C-
terminal truncation mutants was described previously (9). Point mutant GFP-
SH2-B(L231A, L233A) was made by PCR mutagenesis. All mutant constructs
were confirmed by DNA sequencing.
Cells and cell culture. The stock of PC12 cells was purchased from American
Type Culture Collection. PC12 cells were plated on plates coated with 0.1 mg of
rat tail collagen per ml (in 0.02 N acetic acid) and grown at 37°C in 10% CO2 in
Dulbecco modified Eagle medium (DMEM) (Invitrogen) containing heat-inac-
tivated 10% horse serum (ICN) and 5% fetal bovine serum (Invitrogen), sup-
plemented with 1 mM L-glutamine and 1 mM antibiotic-antimycotic (Invitrogen).
PC12 cells stably overexpressing GFP, GFP-SH2-B, GFP-SH2-B(270-670), or
GFP-SH2-B(198-268) were made by transfecting PC12 cells with the con-
structs described above and then growing the cells in selection medium contain-
ing 5 mg of G418 (Invitrogen) per ml for at least 90 days. Cells resistant to G418
were subjected to fluorescence cell sorting based on GFP fluorescence. The
population with the highest expression level (top 5%) was pooled to avoid clonal
variation. Stable pooled cell lines were maintained in complete medium plus 2
mg of G418 per ml. COS-7 cells were cultured in DMEM containing 8% fetal
bovine serum supplemented with 1 mM L-glutamine and 1 mM antibiotic-anti-
mycotic and grown at 37°C in 5% CO2.
Differentiation of PC12 cells. PC12 cells were plated on six-well collagen-
coated plates the day before transfection. Cells were transfected using Lipo-
fectamine and the Plus reagent with various constructs encoding SH2-B mu-
tants or the pEGFP vector alone. After 5 h, the medium was changed to
differentiation medium (DMEM plus 2% horse serum and 1% fetal bovine
serum) that contained 100 ng of NGF per ml. The NGF-containing medium was
replaced every 2 days, and the percentage of differentiation was scored. Cells
with neurite length at least twice the diameter of the cell body were counted as
differentiated cells. The percentage of differentiated cells was determined by
dividing the number of cells that were both transfected and differentiated by the
total number of transfected cells.
Immunoblotting and immunoprecipitation. PC12 cells were harvested into
lysis buffer (50 mM Tris [pH 7.5], 0.1% Triton X-100, 150 mM NaCl, 2 mM
EGTA) and kept on ice for an additional 10 min before centrifugation at 8,250
 g in an IEC/MicroMax centrifuge for 10 min at 4°C. The supernatant was
transferred to a new tube and boiled in sample buffer. Proteins were resolved by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and
then transferred to nitrocellulose paper for Western blot analysis. For coimmu-
noprecipitation, GFP-SH2-B was immunoprecipitated using anti-GFP antibody
and then incubated with protein A agarose. The immunoprecipitated proteins
were resolved by SDS-PAGE.
FIG. 1. Effects of N-terminal truncation mutants of SH2-B on
neuronal differentiation. (A) Schematic representations of various N-
terminal truncation mutants of SH2-B fused to the C terminus of
GFP. The proline-rich domain (P), pleckstrin homology domain (PH),
and Src homology domain SH2 are depicted. The numbers are the
amino acid numbers in the rat sequence of SH2-B. (B) PC12 cells
were transiently transfected with cDNAs encoding either GFP alone,
full-length SH2-B, or the SH2-B mutants depicted in panel A and
then treated with 100 ng of NGF per ml for 4 days. The percentage of
differentiation was determined on day 4 as the number of transfected
and differentiated cells divided by the number of transfected cells. A
total of 150 to 200 transfected cells were counted for each condition in
each experiment. The values are averages  standard errors (error
bars) from three different experiments.
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Immunolocalization. PC12 cells were plated onto poly-L-lysine-coated cover-
slips and transfected the following day with various constructs encoding GFP-
SH2-B fusion proteins using Lipofectamine and the Plus reagents. COS-7 cells
were plated on coverslips and transfected with SH2-B-encoding constructs via
calcium phosphate precipitation. After overnight expression of the transfected
cDNA, cells were fixed with 4% paraformaldehyde. Coverslips were mounted
onto slides with Prolong (Molecular Probe). The subcellular distribution of the
various GFP-SH2-B proteins was determined by GFP fluorescence. To detect
endogenous SH2-B, PC12 cells were plated on the coated chamber slides
(Fisher) and fixed with methanol at 	20°C for at least 30 min. Fixed cells were
incubated with anti-SH2-B antibody (Santa Cruz) (diluted 1:25) for 1 h, with
rabbit anti-goat Alexa 488 antibody (Fab
) (Molecular Probe) (diluted 1:100) for
1 h, and then with 4
,6
-diamidino-2-phenylindole (DAPI) (Molecular Probe) (2
ng/ml) for 5 min. Active ERK was immunostained with active ERK antibody
(diluted 1:250) (Promega) for 1 h, with goat anti-rabbit Alexa 555 antibody
(Molecular Probe) (diluted 1:500) for 1 h, and with 2 ng of DAPI per ml for 5
min. The fixed and stained cells (undifferentiated PC12 cells and COS-7 cells)
were visualized by fluorescence microscopy (Nikon Eclipse TE200) with either
60 (undifferentiated PC12 cells) or 40 (COS-7 cells) objectives. Live, differ-
entiated PC12 cells were visualized using a 20 objective. Images were captured
using a SPOT camera from Diagnostic Instruments, Inc.
RESULTS
Identification of regions of SH2-B important for promot-
ing NGF-induced neurite outgrowth. We and others have
FIG. 2. Subcellular distribution of N-terminal truncation mutants of SH2-B. (A) Schematic representations of various N-terminal truncation
mutants of SH2-B fused to the C terminus of GFP. The proline-rich domain (P), pleckstrin homology domain (PH), and Src homology domain
SH2 are depicted. The numbers are the amino acid numbers in the rat sequence of SH2-B. (B) PC12 cells were transiently transfected with cDNA
encoding vector alone (G), full-length GFP-tagged SH2-B (F), or a GFP-tagged mutant of SH2-B shown in panel A, and designated by the
number of its initial amino acid. Cells were lysed 18 h after transfection. Cell lysates were resolved by SDS-PAGE and immunoblotted with anti-
SH2-B antibody. The migration positions of molecular weight (mw) standards (in thousands) are shown to the left of the gel. (C) PC12 cells were
transiently transfected with cDNAs encoding GFP-tagged full-length SH2-B [GFP-SH2-B(1-670)] or an N-terminal truncation mutant of
SH2-B. The N-terminal truncation SH2-B mutants GFP-SH2-B(170-670), GFP-SH2-B(200-670), GFP-SH2-B(270-670), GFP-SH2-B(397-
670), and GFP-SH2-B(504-670) were used. Cells were fixed 18 h after transfection with 4% paraformaldehyde, and the images were taken using
epifluorescence microscopy. (D) PC12 cells were transiently transfected with cDNAs encoding GFP-tagged full-length SH2-B or an N-terminal
truncation mutant of SH2-B and then treated with 100 ng of NGF per ml for 4 days. Images of live cells were taken on day 4 using epifluorescence
microscopy.
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shown previously that overexpression of SH2-B ( and/or )
enhances NGF-induced neurite outgrowth of PC12 cells (38,
39, 46, 47). To determine which region of SH2-B is required
for its stimulatory effect on neuronal differentiation, we con-
structed a series of cDNAs encoding SH2-B truncation mu-
tants fused to the C terminus of GFP as depicted in Fig. 1A.
PC12 cells were transiently transfected with cDNAs encoding
GFP-tagged wild-type SH2-B or various truncated forms of
SH2-B and grown for 4 days in low-serum medium containing
100 ng of NGF per ml. The differentiation percentage was
determined by dividing the number of differentiated trans-
fected cells by the total number of transfected cells on day 4.
Cells were considered differentiated if they had neurites at
least twice the length of their cell body. As shown in Fig. 1B,
PC12 cells expressing GFP alone showed an average 14.5% of
transfected cells that differentiated in response to NGF. Over-
expression of GFP-SH2-B more than doubled the number of
differentiated cells (to 34.4%). Deletion of the first 169 amino
acids [SH2-B(170-670)] reduced the percentage of differen-
tiated cells to 23.1%. Deleting the N-terminal 269 amino acids
inhibited the ability of SH2-B to enhance neuronal differen-
tiation, with only 15.5% cells being differentiated. These re-
sults suggest that regions of SH2-B between amino acids 1
and 270 are required for the stimulatory effect of SH2-B on
neurite outgrowth.
Subcellular distribution of SH2-B and its N-terminal trun-
cation mutants. To our surprise, when examining the effects of
the different truncated forms of SH2-B on neurite outgrowth,
a difference in the subcellular distribution of the various SH2-
B mutants was observed. Some versions of SH2-B were
found almost exclusively in the cytoplasm, while others were
distributed in both the cytoplasm and nucleus. To charac-
terize this further and to gain insight into how the subcellular
distribution of SH2-B affects its ability to enhance morpho-
logical differentiation of PC12 cells, we set out to identify the
regions of SH2-B that are responsible for its nuclear local-
ization.
Figure 2A depicts a series of N-terminal truncation mutants
of SH2-B for which the subcellular distribution was exam-
ined. PC12 cells were transiently transfected with cDNA en-
coding GFP-tagged full-length SH2-B or a GFP-tagged N-
terminal truncation mutant, and the relative expression levels
and sizes of the ectopically expressed SH2-B were confirmed
by Western blot analysis. As shown in Fig. 2B, the proteins
expressed by the various GFP-SH2-B fusion constructs mi-
grated as proteins of the appropriate estimated sizes. In
addition, the expression levels of these proteins were simi-
lar, suggesting that any differences in the observed subcellular
distribution of these SH2-B mutants were not a consequence
of different levels of overexpression.
The subcellular distribution of N-terminal truncation mu-
tants of SH2-B was examined 18 h after transfection via GFP
green fluorescence (Fig. 2C). Full-length SH2-B localized
predominantly in the cytoplasm at steady state, as did the N-
terminal truncation mutants SH2-B(170-670) and SH2-B
(200-670). However, deletion of additional N-terminal amino
acids resulted in SH2-B(270-670), SH2-B(397-670), and
SH2-B(504-670) in the nucleus and cytoplasm. The same pat-
tern of subcellular distribution of the different forms of SH2-
B was also observed in the differentiated PC12 cells (Fig. 2D).
In general, the nuclear-cytoplasmic transport of proteins larger
than 40 kDa is thought to be via a tightly regulated and energy-
dependent process (15). Thus, the nuclear distribution of these
SH2-B mutants is unlikely due to simple diffusion, because
GFP-SH2-B(270-670), GFP-SH2-B(397-670), and GFP-SH2-
B(504-670) express as 71, 57, and 45 kDa proteins (Fig. 2B)
that would not be expected to diffuse in and out of the nucleus
at a significant rate. Thus, deleting the N-terminal 269 amino
acids shifted the location of SH2-B from primarily cytoplasm
to both the cytoplasm and nucleus. We also examined the
subcellular distribution of myc-tagged SH2-B constructs and
observed the same localization pattern (data not shown), sug-
gesting that the subcellular distribution pattern of the various
forms of SH2-B is not an artifact of using the GFP tag. These
localization results obtained using the SH2-B N-terminal
truncation mutants suggest that SH2-B can enter the nucleus
and that amino acids 200 to 270 are responsible for maintain-
ing SH2-B in the cytoplasm.
Subcellular distribution of C-terminal truncation mutants
of SH2-B. To confirm that sequence between amino acids 200
and 270 constitute the region that causes a shift in the steady-
state subcellular distribution of SH2-B, a series of constructs
encoding C-terminal truncation mutants of SH2-B fused to
the C terminus of GFP were used as depicted in Fig. 3A. When
cells transiently expressing these proteins were treated with
100 ng of NGF per ml for 4 days, full-length SH2-B(1-670)
and SH2-B(1-631) expressed in differentiated PC12 cells lo-
calized primarily in the cytoplasm (Fig. 3B). While SH2-B(1-
260) was also seen in the cytoplasm of differentiated PC12
cells, in contrast, SH2-B(1-200) concentrated in the nucleus.
When only the N-terminal 150 amino acids of SH2-B were
expressed, SH2-B(1-150) also localized to both the cytoplasm
and nucleus.
To visualize the subcellular distribution of SH2-B better,
we took advantage of the larger and flatter morphology of
COS-7 cells. Both full-length SH2-B(1-670) and SH2-B(1-
631) showed a primarily cytoplasmic distribution in COS-7
cells (Fig. 3C). The shift in the location of SH2-B from pri-
marily in the cytoplasm to the cytoplasm and nucleus occurred
when amino acids 200 to 260 were deleted, as with the PC12
cells. Both SH2-B(1-200) and SH2-B(1-150) were found in
the nucleus and cytoplasm (Fig. 3C). Together, these results
FIG. 3. Subcellular localization of the C-terminal truncation mutants of SH2-B. (A) Schematic representations of various C-terminal
truncation mutants of SH2-B fused to the C terminus of GFP. (B) PC12 cells were transiently transfected with cDNAs encoding GFP-tagged
full-length SH2-B [GFP-SH2-B(1-670)] or a C-terminal truncation mutant of SH2-B shown in panel A. The C-terminal truncation SH2-B
mutants GFP-SH2-B(1-631), GFP-SH2-B(1-260), GFP-SH2-B(1-200), and GFP-SH2-B(1-150) were used. The cells were then treated with
100 ng of NGF per ml for 4 days. Images of live cells were taken on day 4. (C) COS-7 cells were transiently transfected with cDNAs encoding
GFP-tagged full-length SH2-B or a C-terminal truncation mutant of SH2-B as indicated. Cells were fixed 18 h after transfection with 4%
paraformaldehyde, and the images were taken using epifluorescence microscopy. DAPI images show nuclei.
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FIG. 4. SH2-B shuttles between the cytoplasm and nucleus. (A) PC12 cells were transiently transfected with cDNA encoding GFP-SH2-B
or GFP. Eighteen hours after transfection, cells were either mock treated (left panels) or treated with 20 nM leptomycin B (LMB) for 3 h (right
panels) before fixation. Images were then taken to determine the subcellular distribution of GFP-SH2-B. DAPI images next to the fluorescence
images showed the localization of the nucleus. (B) COS-7 cells were transiently transfected with GFP-SH2-B or GFP. Eighteen hours after
transfection, cells were either mock treated (left panels) or treated with 20 nM LMB for 5 h (right panels) before fixation. Images were then taken
using epifluorescence microscopy. DAPI images showed the nucleus localization. (C) Quantification of GFP-SH2-B distribution in the cytoplasm
(C) or in the cytoplasm and nucleus (CN) in either PC12 cells or COS-7 cells without or with LMB ( LMB) treatment. A total of 17 to 43 cells
were counted from two experiments per condition. (D) PC12 cells were incubated without or with LMB for 3h before fixation. Endogenous SH2-B
was detected by incubating cells with goat anti-SH2-B antibody and then with rabbit anti-goat Alexa 488. The images were visualized using
epifluorescence microscopy. The corresponding DAPI images show the nuclei. (E) COS-7 cells were incubated without or with LMB for 28 h
before fixation. Endogenous SH2-B was detected and visualized as described for panel D.
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FIG. 4—Continued.
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suggest that amino acids 200 to 260 are essential for SH2-B to
concentrate in the cytoplasm, consistent with the conclusion
drawn from analyzing the N-terminal truncation mutants of
SH2-B (Fig. 2).
Nucleocytoplasmic shuttling of SH2-B. The subcellular
distribution studies of the N- and C-terminal truncation mu-
tants reveal an intriguing possibility: SH2-B shuttles between
the cytoplasm and nucleus. Transport of proteins in and out of
the nucleus is generally thought to rely on their recognition by
soluble shuttling receptors, importins and exportins. The ma-
jority of nuclear export depends on the nuclear export recep-
tor, Crm1 (also called exportin 1). Leptomycin B (LMB) is a
specific inhibitor of Crm1 and is commonly used to prevent
Crm1-dependent nuclear export (15).
To determine whether wild-type SH2-B shuttles between
the cytoplasm and nucleus, the distribution of transiently ex-
pressed full-length GFP-tagged SH2-B was examined in
PC12 cells with or without LMB treatment. Despite its pre-
dominantly cytoplasmic localization, if SH2-B is continuously
shuttling between the cytoplasm and nucleus and is exported
from the nucleus in a Crm1-dependent manner, it would be
expected to accumulate in the nucleus when cells are treated
with LMB. In Fig. 4A, undifferentiated PC12 cells transiently
expressing GFP-SH2-B were treated with 20 nM LMB for 3 h
or not treated with LMB, and the cells were fixed for imaging.
In 94% of the PC12 cells, SH2-B distributed predominant-
ly in the cytoplasm in the absence of LMB (Fig. 4A and C).
In contrast, in the presence of LMB, SH2-B appeared in both
the cytoplasm and the nucleus in 98% of the cells (Fig. 4A
and C).
To visualize the nuclear localization of SH2-B better, pos-
sible cytoplasmic-nuclear shuttling of SH2-B was also exam-
ined in COS-7 cells. Similar to what was found in PC12 cells,
GFP-SH2-B was found mainly in the cytoplasm at steady
FIG. 5. Subcellular distribution of GFP-SH2-B(198-268). (A) Schematic representation of the internal deletion mutant of SH2-B fused to
the C terminus of GFP, GFP-SH2-B(198-268). (B) PC12 cells were transiently transfected with cDNAs encoding either GFP-SH2-B or
GFP-SH2-B(198-268). Cells were fixed, and images were taken using epifluorescence microscopy. DAPI images next to the fluorescence images
showed the nucleus localization. (C) PC12 cells were transiently transfected with cDNA encoding either GFP-SH2-B or GFP-SH2-B(198-268)
and then treated with 100 ng of NGF per ml for 4 days. Live images of differentiated PC12 cells were taken on day 4 to show the localization of
GFP-SH2-B or GFP-SH2-B(198-268). (D) COS-7 cells were transiently transfected with cDNA encoding either GFP-SH2-B or GFP-SH2-
B(198-268). Cells were fixed 18 h after transfection, and images were taken using epifluorescence microscopy. DAPI images next to the
fluorescence images were used to show the nucleus localization.
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FIG. 6. Point mutations in the putative NES motif in SH2-B inhibit the nuclear export of SH2-B. (A) Known NESs in various classes of
proteins and the putative NES in SH2-B. The arrows point to the two leucines in SH2-B being mutated. (B) PC12 cells were transiently
transfected with the cDNA encoding the GFP-fused SH2-B point mutant, SH2-B(L231A, L233A). Cells were fixed 18 h after transfection
(undifferentiated). Another set of cells was treated with 100 ng of NGF per ml for 4 days, and live images of the differentiated PC12 cells were
taken. (C) Quantification of the localization of GFP-SH2-B, GFP-SH2-B(198-268), or SH2-B(L231A, L233A) in either the cytoplasm (C) or
in both the cytoplasm and nucleus (CN). A total of 61 to 173 differentiated PC12 cells from three experiments were counted for each construct.
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state in 78% of the cells but accumulated in the nucleus after
5 h of LMB treatment in 96% of cells (Fig. 4B and C). These
results strongly suggest that SH2-B constitutively shuttles be-
tween the cytoplasm and nucleus. The constitutive cytoplas-
mic-nuclear shuttling of SH2-B was also observed using myc-
tagged SH2-B (data not shown).
The experiments presented thus far used overexpressed
wild-type or mutant forms of SH2-B. We asked whether en-
dogenous SH2-B also undergoes nucleocytoplasmic shuttling.
Again, we treated both PC12 and COS-7 cells with LMB for
various times and determined the subcellular distribution of
endogenous SH2-B by performing indirect immunofluores-
cence microscopy. As predicted from the overexpression stud-
ies, we observed SH2-B being excluded from the nucleus of
PC12 cells at steady state and distributed in both the cytoplasm
and nucleus after LMB treatment (Fig. 4D). In COS-7 cells,
SH2-B was also shown to be excluded from the nucleus in the
absence of LMB and to appear in the nucleus after 8 h or
longer of LMB treatment (Fig. 4E).
Nuclear localization of SH2-B lacking the region required
for nuclear export. Both N-terminal and C-terminal truncation
analysis of SH2-B point to a region between amino acids 200
and 260 being required for the nuclear export of SH2-B. To
determine whether this region is necessary for SH2-B to exit
the nucleus, we next examined the subcellular distribution of
an internal deletion mutant, SH2-B(198-268), lacking this
region (Fig. 5A). As shown in Fig. 5B to D, SH2-B(198-268)
localized almost exclusively in the nucleus. This nuclear distri-
bution was pronounced in undifferentiated PC12 cells (Fig. 5B)
as well as in differentiated PC12 cells (Fig. 5C) and in COS-7
cells (Fig. 5D). Thus, it is very likely that amino acids 198 to
268 contain a signal for the nuclear export of SH2-B.
SH2-B contains a conserved NES. Closer examination of the
sequence between amino acids 200 and 260 in SH2-B re-
vealed a conserved nuclear export sequence (NES). The NES
identified thus far has a relatively loosely defined motif,
LX2-3LX2-4LXL (2, 3, 32). As shown in Fig. 6A, a putative NES
motif of SH2-B is present between amino acids 224 and 233. As
previously shown for 14-3-3, a scaffolding protein that shuttles
between the cytoplasm and nucleus and participates in multi-
ple signaling pathways, the C-terminal amino acids LXL are
essential for nuclear export activity (3). Therefore, point mu-
tations were introduced to change amino acids L231 and L233
of SH2-B to alanines. and the subcellular distribution of
GFP-SH2-B(L231A, L233A) was examined. When GFP-
SH2-B(L231A, L233A) was transiently expressed in PC12
cells, it accumulated in the nucleus, consistent with it being
defective in nuclear export. As expected, this nuclear localiza-
tion was observed in both undifferentiated and differentiated
PC12 cells (Fig. 6B). Comparing the distribution in differenti-
ated PC12 cells of wild-type SH2-B and the nuclear export-
deficient mutants, wild-type SH2-B was found to reside pre-
dominantly in the cytoplasm in 97% of the cells at steady
state, whereas both SH2-B(198-268) and SH2-B(L231A,
L233A) were concentrated in the nucleus in 93% of the cells
(Fig. 6C).
Effects of export-impaired SH2-B mutants on neuronal
differentiation. As shown in Fig. 1, PC12 cells overexpressing
SH2-B and SH2-B(170-670) showed an increased percent-
age of differentiated cells compared to control cells (trans-
fected with vector only) when the cells were treated with NGF.
In contrast, cells overexpressing the N-terminal truncation mu-
tants SH2-B(270-670) and SH2-B(504-670) did not show
increased neurite outgrowth. Full-length SH2-B(1-670) and
SH2-B(170-670) are found predominantly in the cytoplasm,
whereas SH2-B(270-670) and SH2-B(504-670) are found in
both the cytoplasm and nucleus (Fig. 2). These findings led us
to speculate that the “proper” locale of SH2-B is vital for
the ability of SH2-B to enhance NGF-induced neurite out-
growth.
To test this hypothesis, we investigated the effects of the nu-
clear export-impaired SH2-B(198-268) and SH2-B(L231A,
FIG. 7. Effect of SH2-B(198-268) and SH2-B(L231A, L233A)
on neuronal differentiation. (A) PC12 cells were transiently trans-
fected with the cDNA encoding the vector alone (GFP), GFP-SH2-B,
or GFP-SH2-B(198-268) as indicated. Cells were then treated with
100 ng of NGF per ml for 4 days, and the percentage of differentiation
was determined as described in the legend to Fig. 1. A total of 300 to
450 transfected cells were counted for each condition in each experi-
ment, and the values are averages  standard errors (error bars) from
three different experiments. (B) PC12 cells were transiently transfected
with the cDNA encoding the vector alone, GFP-SH2-B, or GFP-
SH2-B(L231A, L233A) as indicated. Cells were then treated with 100
ng of NGF per ml for 4 days, and the percentage of differentiation was
determined as described in the legend to Fig. 1. A total of 333 to 870
transfected cells were counted for each condition in each experiment,
and the values are averages  standard deviations (error bars) from
two different experiments.
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L233A) mutants on NGF-induced neurite outgrowth. Similar
to cells expressing the N-terminal deletion mutants SH2-B
(270-670) and SH2-B(504-670), PC12 cells transiently ex-
pressing the internal deletion mutant GFP-SH2-B(198-268)
or the point mutant GFP-SH2-B(L231A, L233A) showed
no enhancement in NGF-induced neurite outgrowth com-
pared to cells expressing GFP alone (Fig. 7B). These results
suggest that SH2-B needs to reside predominantly in the cy-
toplasm to enhance NGF-induced neurite outgrowth in PC12
cells.
Effects of SH2-B mutations on NGF-induced activation of
TrkA and ERKs 1 and 2. One mechanism by which the NES of
SH2-B may contribute to NGF-induced morphological dif-
ferentiation is by enhancing the ability of SH2-B to activate
one or more NGF signaling pathways. When NGF binds to its
receptor TrkA, TrkA rapidly becomes activated and phosphor-
ylated on tyrosines with tyrosine 490 being a primary phos-
phorylation site (34, 35). We and others have shown that NGF
stimulation enhances the interaction between SH2-B and
TrkA (39, 46). SH2-B has also been reported to enhance and
prolong NGF stimulation of TrkA phosphorylation on Tyr 490
and activation of Akt and ERKs 1 and 2 (38, 55).
To determine whether the nuclear export-impaired SH2-
B mutants lose or retain the ability to regulate NGF sig-
naling via TrkA, we made PC12 cell lines stably overexpress-
ing GFP, GFP-SH2-B, GFP-SH2-B(198-268), or GFP-
SH2-B(L231A, L233A). To avoid clonal variation, we pooled
the clones with the highest (5%) level of expression. The sub-
cellular distribution of SH2-B and its mutants in these stable
cell lines was similar to that seen in the transiently transfected
cells (data not shown). The relative abilities of these stably
transfected cell lines to differentiate in response to NGF mir-
rored the relative abilities of the transiently transfected cells to
differentiate, with SH2-B enhancing NGF-induced neurite
outgrowth and the nuclear export-deficient forms of SH2-B
having no effect (data not shown).
First, we examined whether nuclear export SH2-B mutants,
such as SH2-B, interacted with activated TrkA. PC12 cells
stably expressing GFP, GFP-SH2-B, GFP-SH2-B(198-
268), or GFP-SH2-B(L231A, L233A) were incubated in se-
rum-free medium overnight. Cells were then treated with so-
dium vanadate (a phosphatase inhibitor) for 1 h prior to NGF
stimulation (100 ng/ml, 10 min) and GFP-SH2-B was immu-
noprecipitated using anti-GFP antibody. The immunoprecipi-
tated proteins were resolved by SDS-PAGE and blotted first
with antiphosphotyrosine antibody and then reprobed with
anti-SH2-B antibody. As shown in Fig. 8A, GFP-SH2-B
(198-268) and GFP-SH2-B(L231A, L233A), like wild-type
GFP-SH2-B, were capable of binding to phosphorylated TrkA,
though to a lesser extent. This result suggests that these two
nuclear export mutants are functional proteins. It also sug-
gests that failure to interact with TrkA is not the reason why
the nuclear export-defective mutants are loss-of-function mu-
tants.
Next we investigated the effect of mutating the NES of
SH2-B on its ability to enhance NGF activation of ERKs 1
and 2. Phosphorylation of ERKs 1 and 2 in cells expressing
GFP alone was highest 10 min after NGF stimulation and then
declined rapidly. Overexpression of SH2-B showed substan-
tially enhanced phosphorylation of ERKs 1 and 2 at both 90
and 240 min after NGF challenge. Like cells expressing GFP-
SH2-B, cells expressing the GFP-SH2-B(L231A, L233A)
mutant showed elevated stimulation 240 min after the addition
of NGF (Fig. 8B), but not after 90 min. NGF promotes the
nuclear localization of ERKs 1 and 2 (18, 52).
To determine whether SH2-B(L231A, L233A) might alter
the subcellular distribution on ERKs 1 and 2, we examined the
localization of the active forms of ERKs 1 and 2 in stable cell
lines. PC12 cells stably expressing GFP, GFP-SH2-B, or
GFP-SH2-B(L231A, L233A) were incubated in serum-free
medium overnight. After 1 h of treatment with 100 ng of NGF
per ml, cells were fixed, and the distribution of endogenous
active ERKs 1 and 2 was visualized using indirect immunoflu-
orescence microscopy (Fig. 8C). After 1 h of NGF treatment,
active ERKs 1 and 2 were seen in the nucleus in cells express-
ing GFP, GFP-SH2-B, or GFP-SH2-B(L231A, L233A). There
was no obvious localization defect of active ERKs 1 and 2 in
cells expressing GFP-SH2-B(L231A, L233A). Therefore, we
conclude that the nuclear export mutant GFP-SH2-B(L231A,
L233A) does not appreciably alter the subcellular distribution
of ERKs 1 and 2. Therefore, the loss-of-function phenotype of
SH2-B(L231A, L233A) on NGF-induced neurite outgrowth
is unlikely to be attributable to decreased NGF activation of
ERK proteins or to impaired transport of ERK proteins into or
out of the nucleus.
DISCUSSION
Members of the SH2-B family of proteins were originally
identified as binding proteins of receptor tyrosine kinases, the
cytokine receptor-associated JAK2, or phosphorylated tyro-
sines within receptors of the immune system (39, 45, 48). The
facts that this binding was ligand dependent and that SH2-B
family members lack a transmembrane domain sequence but
contain an SH2 domain led to the hypothesis that SH2-B
family members were most likely cytoplasmic and recruited to
phosphorylated tyrosines within membrane receptor/tyrosine
kinase complexes. The results of immunolocalization studies
supported the hypothesis that SH2-B localized to the plasma
membrane before and after ligand stimulation, to mem-
brane ruffles after ligand stimulation, and to the cytoplasm (17,
47).
In the present study in which SH2-B was overexpressed in
both undifferentiated and differentiated PC12 cells and in
COS-7 cells, some SH2-B could be visualized at the plasma
membrane, though most of the SH2-B was found in the
cytoplasm. However, while wild-type SH2-B as well as SH2-
B lacking its first 170 or 200 amino acids localized predomi-
nantly in the cytoplasm, surprisingly, truncation mutants SH2-
B(270-670), SH2-B(397-670), and SH2-B(504-670) were
found in both the cytoplasm and nucleus (Fig. 2). These results
suggest that while equilibrium favors SH2-B being primarily
in the cytoplasm, SH2-B shuttles continuously between the
cytoplasm and nucleus.
These results further suggest that the nuclear export signal
responsible for the export of SH2-B out of the nucleus is
located between amino acids 200 and 270 of SH2-B. In the
absence of these amino acids, SH2-B can enter the nucleus
but is not capable of exiting. In support of amino acids 200 to
270 containing the nuclear export signal, an internal deletion
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mutant of SH2-B lacking these amino acids was located in the
nucleus. Mutating two leucines in a putative nuclear export
signal within this region in the context of full-length SH2-B
also caused SH2-B to localize to the nucleus. These results
further support the hypothesis that SH2-B shuttles between
the cytoplasm and nucleus. The sequences containing the nu-
clear export motif are identical among the four known iso-
forms of SH2-B, so it is likely that nucleocytoplasmic shuttling
is common for all four isoforms. The fact that both overex-
pressed wild-type SH2-B and endogenous SH2-B are found
predominantly in the cytoplasm suggests that SH2-B is con-
tinuously cycling between the nucleus and cytoplasm, with the
ratio of nuclear export to import favoring most of the SH2-B
residing in the cytoplasm at any given time. The nuclear export
inhibitor LMB causes both overexpressed wild-type SH2-B
and endogenous SH2-B to accumulate in the nucleus, sup-
porting the notion that endogenous SH2-B shuttles constitu-
tively between the cytoplasm and nucleus. NGF did not no-
ticeably affect the steady-state distribution of SH2-B (data
not shown); however, it is possible that NGF affects the kinet-
ics of nucleocytoplasmic shuttling of SH2-B.
The finding of SH2-B shuttling between the cytoplasm and
nucleus raises the question of whether this nucleocytoplasmic
shuttling is required for SH2-B to enhance NGF-induced
neurite outgrowth. Mutating the NESs, either by truncation
[SH2-B(270-670)], internal deletion [SH2-B(198-268)], or
point mutations [SH2-B(L231A, L233A)], resulted in a loss
of the ability of SH2-B to enhance NGF-induced neurite
outgrowth (Fig. 1 and 7). One possible explanation for the loss
of this ability is that enhancement of neurite outgrowth re-
quires SH2-B to reside some of the time in the cytoplasm
and/or plasma membrane and some of the time in the nucleus.
One can envision cytoplasmic SH2-B providing a reservoir of
SH2-B to bind to TrkA in response to NGF, which upon the
appropriate posttranslational modification, subsequently goes
to the nucleus either as a nuclear import shuttle for other
signaling proteins or as a scaffolding protein for transcription
factor complexes. Alternatively, one can envision SH2-B be-
ing required to facilitate the export of proteins that mediate or
regulate transcription. ERKs 1 and 2 were possible candidates
for such a shuttling event, because of the key role they are
known to play in NGF-induced neurite outgrowth of PC12
cells and their nuclear import and export mechanism is still
controversial (7, 12, 24, 31, 61). However, our results indicate
that cells expressing the nuclear export-defective forms of
SH2-B do not show substantially reduced NGF-induced ac-
tivation and nuclear localization of ERKs 1 and 2 compared to
cells expressing wild-type SH2-B. We also think it unlikely
that the export-deficient mutants sequester vital NGF signaling
proteins in the nucleus, because unlike the SH2 domain-de-
fective mutant SH2-B(R555E), they do not act as dominant
negatives and block NGF-induced neurite outgrowth. One pos-
sible explanation is that after SH2-B binds to TrkA and ini-
tiates one or more signaling pathways important for neurite
outgrowth, it moves to the nucleus. Eventually, however, it
recycles back to the cytoplasm where it can repeat the cycle. In
contrast, while the nuclear export-deficient mutants would be
able to initiate one round of signaling, they would have diffi-
culty recycling back to the cytoplasm from the nucleus. This
latter hypothesis is consistent with our recent results indicating
that nuclear import SH2-B mutants enhance the morpholog-
ical differentiation of PC12 cells more than wild-type SH2-B
does (T. J. Maures and C. Carter-Su, unpublished data).
Although the exact mechanism by which SH2-B enhances
neurite outgrowth, as well as the role of nuclear SH2-B,
remains unclear, our results strongly suggest a mechanism that
involves SH2-B interacting with extranuclear components
participating in the process of neurite outgrowth. Several cy-
toplasmic proteins have been shown to participate in neuronal
differentiation, including the actin regulatory proteins, LIM
kinases, and their downstream effectors, such as the Rho fam-
ily of GTPases, Cdc42, Rac, and Rho (27, 28). It is possible that
SH2-B affects the function of some of these proteins by af-
fecting their subcellular localization or by serving as a scaffold-
ing protein that brings them into close proximity to appropriate
regulatory or effector proteins, similar to how the Saccharomy-
ces cerevisiae scaffolding protein Ste5 organizes and localizes
the MAPK cascade of the mating pathway to respond appro-
priately to a pheromone stimulus (1, 6, 20, 29, 50, 56). Rac was
a logical candidate for several reasons. It has been shown to
regulate neuronal differentiation via modulating growth cone
collapse during neurite outgrowth (27, 30, 51) and to bind
constitutively, either directly or indirectly, to the N-terminal
second proline-rich region of SH2-B (amino acids 85 to 106)
(9). However, while the SH2-B truncation mutant SH2-B
(170-670) lacking this proline-rich region showed a reduced
ability to promote NGF-induced neurite outgrowth compared
to wild-type SH2-B (Fig. 1B), neurite outgrowth was not as
reduced as in the cells overexpressing the mutants lacking NES
(Fig. 7). This finding implies that Rac is not the only player in
SH2-B-mediated neuronal differentiation, if it is one. Other
potential players include microtubule-associated proteins
FIG. 8. Effect of a nuclear export-defective mutant of SH2-B on NGF signaling. (A) PC12 cells stably expressing either GFP, GFP-SH2-B,
GFP-SH2-B(L231A, L233A), or GFP-SH2-B(198-268) as indicated were incubated in serum-free medium overnight and then pretreated with
sodium vanadate for 1 h before stimulation without (	) with () 100 ng of NGF per ml for 10 min. Cell lysates were incubated with anti-GFP antibody
and then with protein A agarose. The immunoprecipitated complex was resolved by SDS-PAGE and immunoblotted with antiphosphotyrosine antibody
(top gel) and then reprobed with anti-SH2-B antibody (bottom gel). IP, immunoprecipitation; IB, immunoblotting. (B) PC12 cells stably expressing
either GFP, GFP-SH2-B, or GFP-SH2-B(L231A, L233A) were incubated in serum-free medium overnight and stimulated with 100 ng of NGF per
ml for 0, 10, 90, and 240 min (240
). Lysates from these cell lines expressing GFP, GFP-SH2-B, or GFP-SH2-B(L231A, L233A) were resolved by
SDS-PAGE, and the blot was incubated with anti-phospho-ERKs 1 and 2 (anti-pERK1/2). The highest level of phosphorylated ERKs 1 and 2 in each
experiment was set at 100. The values are the averages  standard errors (error bars) from three different experiments. (C) PC12 stable cell lines were
treated with 100 ng of NGF per ml for 1 h as described for panel B and then fixed and incubated with a rabbit antibody against active phosphorylated
ERK (pERK) and then with goat anti-rabbit Alexa 555 antibody. DAPI images reveal the nuclei. The images were taken using epifluorescence
microscopy.
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and focal adhesion molecules. Paxillin and its binding part-
ner Pyk2 (a focal adhesion kinase) have been shown to par-
ticipate in NGF-induced Ca2 mobilization important for
cytoskeletal reorganization and neurite and growth cone func-
tions (22, 36). Whether SH2-B affects the activity or subcel-
lular distribution of any of these proteins remains to be deter-
mined.
The fact that the nuclear import-deficient forms of SH2-B
promote neuronal differentiation of PC12 cells while nuclear
export-deficient forms of SH2-B do not rules out the possi-
bility that nuclear SH2-B functions in some other cellular
functions or even helps to fine tune the differentiation pro-
gram. For example, nuclear SH2-B may contribute to the
antiapoptotic effects of NGF. We have recently shown that
SH2-B can affect the distribution of FKHR transcription fac-
tors, FKHR (FOXO 1) and FKHRL1 (FOXO 3) (55). By
enhancing the retention of FKHR in the cytoplasm or pro-
moting its nuclear export, SH2-B may contribute to cell sur-
vival.
In summary, the present study provides the first evidence
that the ubiquitously expressed adapter protein SH2-B shut-
tles between the cytoplasm and nucleus, making SH2-B one
of a relatively few examples of a membrane receptor binding
partner that undergoes nucleocytoplasmic shuttling. In addition,
we identify a nuclear export motif, GERWTHRFERLRLSR,
required for the nuclear export of SH2-B. This sequence is
conserved in the four known isoforms of SH2-B, thus implying
that all isoforms of SH2-B undergo nucleocytoplasmic shut-
tling. The cytoplasmic localization of SH2-B appears to be
important for the ability of SH2-B to enhance morphological
differentiation of PC12 cells. The finding of nucleocytoplasmic
shuttling of SH2-B raises the interesting possibility that SH2-
B might facilitate shuttling of other proteins into and/or out
of the nucleus or help assemble specific transcriptional com-
plexes involved in the regulation of NGF-induced neuronal
differentiation and/or neuronal survival. SH2-B was previ-
ously thought to be restricted to the cytoplasm and plasma
membrane. Therefore, the results of this study also emphasize
that caution must be used when searching for a function for
a protein on the basis of its steady-state subcellular localiza-
tion.
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